Educell ltd.

Medical biotechnology, Cell therapy
Prevale 9, 1236 Trzin
Postal code
Contact person's name
Lenart Girandon
Short description of the company
Educell is a biopharmaceutical company, which is (co)developing and producing advanced treatments (ATMPs) for companies and hospitals but most importantly for the benefit of patients.
Company`s description
Educell is a biopharmaceutical CDMO (contract development and manufacturing organization) specialized on cell and gene therapies (ATMPs - advanced therapy medicinal products) situated in EU. Educell has 25 years of experience on cell therapy and regenerative medicine, starting with cultivated chondrocytes, following with mesenchymal stromal/stem cells and now focusing on CAR-T therapy and some other immune therapies. With our high standard of quality, state of the art GMP certified laboratories, range of EU-compliant regulatory approvals and experienced personnel, we can offer a wide support to any institution developing their own ATMP.

Our expertise mainly encompasses the following topics:
  • automated and closed system adherent cell cultivation (mesenchymal stromal/stem cells, chondrocytes, fibroblasts, keratinocytes, etc.)
  • CAR-T manufacturing, upgrading from laboratory grade to GMP grade technology
  • extracellular vesicle production in automated closed system
  • Quality control, Quality assurance, etc.
  • Releasing the batches of cells according to European legislation
  • Help with clinical trial setup, finding interested clinicians in Slovenia, monitoring the Slovenian part of clinical trial.

Besides our CDMO services, we also have proprietary technologies with the potential to be registered as an ATMP in EU, thus we are seeking for investments into the technologies:
  • Technology for cultivation of CD34 positive (hematopoietic stem) cells to be used as an alternative to normal bone marrow transplantation or 2 cord blood transplantations with better outcomes for the patients (Licenced in)
  • MSC product that has been tested in real-world clinical setup for graft-versus-host disease (GvHD, on pediatric and adult patients), Crohns disease, COVID-19, Sacroiliitis, Osteoarthritis, etc.
  • CAR-T technology against CD 19 based on 2nd generation CAR and 3rd generation of lentivirus (Licenced in)

Partner search
Any institution developing their own ATMP willing to outsource part of their development and manufacturing Investors, willing to invest into one of the technologies in possession
ATMPs, advanced therapies, Cell and gene therapy
Short content description
As experts in the field of cell and gene therapy with state of the art GMP certified facilities for automated closed system cell therapy production, we are seeking for collaborations. We are interested in (co)developing ATMPs, their initial clinical trials and help in bringing solutions to the patients in need.
The programme is co-financed by the Slovenian Enterprise Fund and the European Union, namely from the European Fund for Regional Development. It is carried out on the basis of the Substantial Support of Fund Recipients (SME) programme from 2018 to 2023 within the framework of the Operational Programme for the Implementation of European Cohesion Policy from 2014 to 2020.